The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.00
Bid: 70.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 30.00 (42.857%)
Open: 85.00
High: 85.00
Low: 85.00
Prev. Close: 85.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

23 Jul 2015 07:00

RNS Number : 8211T
Biome Technologies PLC
23 July 2015
 



 

23 July 2015

Biome Technologies plc

 

 ("Biome", "the Company" or "the Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes its trading update for the six-month period ended 30 June 2015. The interim results are expected to be announced on 2 September 2015.

 

Trading Update

Total Group Revenues for the first half were £2.1m (H1 2014 £2.3m), including revenues for the second quarter of 2015 of £0.9m (Q1 2015: £1.1m). The turnover for the second quarter maintains the significant progress made in the first quarter of 2015 albeit partly constrained by later phasing of shipments from the RF Technologies Division.

 

The Group's cash position at 30 June 2015 was £1.8m (31 March 2015: £2.3m), reflecting both an increase in working capital ahead of expected shipments in Q3, new product development costs and trading performance.

 

 

Bioplastics Division

Revenues generated by the Bioplastics Division in the first half of 2015 totalled £1.0m (H1 2014 £1.1m).

 

Order levels of the division's commercialised products have recovered substantially in the first half of this year, driven by an improvement in the US market which has seen demand return to levels broadly similar to those seen in the first half of 2014.

 

Additionally, the second half of this year should be favourably impacted by a new product line we have developed reaching its commercialisation phase; initial order rates are already encouraging.

 

Three grant supported research collaborations focused on bio-based materials, highlighted in previous statements, commenced in the first half.

 

Stanelco RF Technologies Division

Revenues for this division in the first half of 2015 were £1.0m (2014: £1.2m). A robust and significant order book for the remainder of the year should see the turnover weighting for the second half substantially above that of the first half of 2015.

 

The recently announced signing of a £1.1m contract to supply optic fibre furnaces in the second half of the year will add considerably to the division's existing pipeline. Additional enquiries indicate that the optic fibre furnace market is more buoyant than it has been for some time, with customers seeking upgrades as well as additional capacity. The contract with a customer from a regulated industry is progressing on time and to plan with the delivery of the first system anticipated in the second half.

 

Group Outlook

Group revenues at the mid-year point are in line with the Board's expectations with a reduced operating loss during the period relative to those expectations. The Board is confident that momentum in revenue growth should accelerate in the second half of the year.

 

-Ends-

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPKBDKABKDKOB
Date   Source Headline
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.